Safety of long-acting β2-agonists in the management of asthma: A primary care respiratory alliance of Canada perspective;Innocuité des β2-agonistes dans la prise en charge de l'asthme: Un point de vue de la primary care respiratory alliance of Canada

Canadian Family Physician

Volumn 56, Issue 2, 2010, Pages 119-124

  D'Urzo, Anthony D ^a,b   Jugovic, Pieter ^c   Bouchard, Jacques ^d   Jhirad, Reuven ^a   Tamari, Itamar ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Primary Care Lung Clinic   (Canada)

^c TORONTO EAST GENERAL HOSPITAL   (Canada)

^d Centre Hospitalier de la Malbaie   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; BUDESONIDE PLUS FORMOTEROL FUMARATE DIHYDRATE; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; TERBUTALINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; INHALER; LUNG FUNCTION; MEDICAL DECISION MAKING; MONOTHERAPY; NOTE; PRIMARY MEDICAL CARE; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; RISK REDUCTION; SYMPTOM;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS;

EID: 77649303681     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. US Food and Drug Administration [website]. Transcript for December 11, 2008 meeting. Rockville, MD: US Food and Drug Administration; 2009. Available from: www.fda.gov/ohrms/dockets/ac/08/transcripts/2008-4398t2-day2. pdf. Accessed 2009 Dec 16.
2. Jaeschke R, O'Bryne PM, Mejza F, Nair P, Lesniak N, Brozek J, et al. The safety of long-acting ß-agonists among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med 2008;178(10):1009-16. Epub 2008 Sep 5.
3. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting ß-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33(1):21-32. Epub 2008 Sep 3.
4. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 2009;360(16):1592-5.
5. Drazen JM, O'Byrne PM. Risks of long-acting beta agonists in achieving asthma control. N Engl J Med 2009;360(16):1671-2.
6. Ernst P, McIvor A, Ducharme FM, Boulet LP, FitzGerald M, Chapman KR, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145(9):692-4.
7. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034-7.
8. Nelson HS, Weiss ST, Bleecker ER, Yansey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26. Erratum in: Chest 2006;129(5):1393.
9. Salpeter SR, Buckley NS, Orminston TM, Salpeter EE. Meta-analysis: effect of long-acting ß2-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144(12):904-12. Epub 2006 Jun 5.
10. D'Urzo AD, Chapman KR, Carter A, Hargreave FE, Fitzgerald M, Tesarowski D. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001;119(3):714-9.
11. Global Initiative for Asthma [website]. Global strategy for asthma management and prevention. Bethesda, MD: Global Initiative for Asthma; 2008. Available from: www.ginasthma.org/Guidelineitem. asp??l1=2&l2= 1&intId=1561. Accessed 2009 Dec 16.
12. National Heart, Lung and Blood Institute [website]. Guidelines for the diagnosis and management of asthma (EPR-C). Bethesda, MD: National Heart, Lung and Blood Institute; 2007. Available from: www.nhlbi.nih.gov/guidelines/ asthma/. Accessed 2008 Dec 22.
13. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158(3):924-30.
14. 2-adrenoceptor agonist single-inhaler combination for both maintenance and rescue therapy: a paradigm shift in asthma management. Treat Respir Med 2006;5(6):385-91.
15. McIvor RA, Chapman KR. The coming of age of asthma guidelines. Lancet 2008;372(9643):1021-2.
16. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne PM, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteriods Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11.
17. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170(8):836-44. Epub 2004 Jul 15.